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Abstract

The varicella zoster virus is a member of the human herpes virus family. This virus
infects humans in temperate regions around the world and produces a primary varicella infection,
commonly known as “chickenpox” (Bricout, 2014). Subsequently, the virus becomes latent in
the sensory ganglia waiting for an opportune time to reactivate as herpes zoster (shingles). There
are over one million cases of herpes zoster cases in the United States annually (Weaver, 2007).
Episodes of herpes zoster typically cause severe pain and distress and up to a third of these
patients develop a chronic neuropathic pain syndrome known as postherpetic neuralgia (PHN).
In 2006, the Food & Drug Administration (FDA) approved the Zostavax ®, a vaccine to prevent
outbreaks of herpes zoster. This independent study aims to determine the incidence of
postherpetic neuralgia in immunized individuals versus those who have not been vaccinated for
prevention of herpes zoster.
Keywords: postherpetic neuralgia, prevention, herpes zoster, zoster vaccine, and Zostavax.
Background
Herpes zoster, also known as shingles, is a viral infection caused by reactivation of a
latent varicella zoster virus (VZV). This virus becomes latent in the sensory ganglia of the
affected person and reappears as herpes zoster (Gabutti, Valente, Sulcaj, & Stefanati, 2014) in
approximately 20-30% of the population (Jeon, 2015). This reoccurrence is thought to be related
to the normal aging process in which there is a decrease in the overall immune response (Bricout
et al., 2014). Specifically, there is less varicella zoster specific T-cell mediated immunity in the
later years of life. This theory holds true for immune compromised patients, who are also at
increased risk for developing the infection. However, 90% of individuals with herpes zoster have
otherwise intact immune responses, which makes it very difficult for practitioners to predict
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those at increased risk. Nevertheless, identified risk factors may include immune compromise,
sex, family history of herpes zoster, ethnicity, physical or emotional trauma, stress, diabetes,
depression, or genetic predisposition (Bricout et al., 2014, p. 2).
The patient infected with herpes zoster typically presents with a painful erythematous
skin lesion in the affected dermatome (Jeon, 2015). It is classically a vesicular lesion, occurring
unilaterally on a single dermatome (Bricout et al., 2014). The location correlates to the sensory
ganglion in which the latent varicella virus was reactivated. Greater than 50% of herpes zoster
infections occur in the thoracic dermatomes. The cranial region is the next most common, and
potentially more severe, as it may involve the “ophthalmic division of the trigeminal nerve”
(Bricout et al., 2014).
The pain related to herpes zoster occurs as the virus replicates within the basal ganglia,
damaging the nerve (Kanbayashi & Hosokawa, 2013). There are three distinctive phases of pain
response with this disease. The first is the prodromal period. This period occurs prior to the onset
of rash and the patient may or may not experience pain. Next, the acute phase begins with a rash
that generally lasts 2-4 weeks. The chronic pain phase is also considered to be the phase of
postherpetic neuralgia (PHN). This is pain that occurs intermittently or continues for greater than
three months after onset of the rash (Bricout et al., 2014).
Postherpetic neuralgia often takes several forms including allodynia, hyperpathia, and
dysesthesia (Kanbayashi & Hosokawa, 2013). Allodynia refers to the perception of nonpainful
stimuli as painful. Hyperpathia describes the intensification of slightly painful stimulation that is
perceived as agonizing. Dysesthesia presents through atypical sensations that lack the presence
of stimuli. The pain associated with postherpetic neuralgia can be debilitating and greatly impact
the individual’s quality of life. This is especially true in elderly adults where herpes zoster may

HERPES ZOSTER VACCINATION

5

impair activities of daily living resulting in altered mood or depression. Even more burdensome
is the fact that the neuropathic pain can be very difficult for healthcare providers to manage.
Prevention of herpes zoster has improved through the development of the Zostavax ®, a
live, attenuated varicella zoster virus vaccine. This vaccine specifically enhances the varicella
zoster virus cell mediated immunity (Kanbayashi & Hosokawa, 2013). Obviously, prevention of
herpes zoster alleviates risk of the patient developing postherpetic neuralgia. While the vaccine is
currently approved in the United States for patients over fifty years old, it is not recommended
until the age of sixty (Kanbayashi & Hosokawa, 2013). Only fifty year olds who have had an
outbreak of herpes zoster or those with a chronic disease such as diabetes mellitus, chronic renal
failure, or rheumatoid arthritis are recommended to receive the vaccination. The efficacy of the
vaccine is also limited to only five years (Kanbayashi & Hosokawa, 2013).
At this time there is no proven effective prophylaxis or recommendation for the
prevention of postherpetic neuralgia (Kanbayashi & Hosokawa, 2013). This independent study
aims to determine the efficacy of the varicella zoster vaccine in preventing the condition. The
foundation of this report is based on the case of a 52 year old otherwise healthy male who
presented with an acute phase herpes zoster infection.
Case Report
History
This independent study is based on the case of a fifty-two year old male patient who
presented with left sided facial irritation, pruritus, erythema, and vesicular rash. He stated that his
symptoms began with an intensely “itchy” feeling near his left eye one week ago. Three days
prior to our encounter, he developed a “rash and blisters”. He states that his symptoms have
become more intense since the onset. The patient describes himself to be generally healthy with
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no other complaints at the time of visit. He relates that until recently he was unable to afford
health insurance and therefore does not have a primary care provider. He is also not up to date
with recommended screenings for his age. The patient did report having all recommended
immunizations as a child, however denies any in his adult years. He denies any surgeries or
severe conditions as a child, although he does recall being told he had chickenpox when he was
very young. Currently, he is employed full-time as a seasonal tax preparer and regularly
participates as a standardized patient model for the local nursing and medical schools. The
patient is single, never married, and has no children. He denies any use of tobacco, illicit drug, or
alcohol products, and has no known allergies. He does not take any scheduled medications or
nutritional supplements, however does take acetaminophen as needed for mild pain relief. I
conducted a thorough review of family history and the patient denied having any relatives with
known cardiovascular disease, cancer, stroke, or diabetes mellitus.
Review of Systems
A complete review of systems was completed at the time of his examination. The patient
denied fever, chills, fatigue, or weight changes. As previously discussed, the patient did relate to
having a pruritic, vesicular rash near his left eye. He denied any other skin rash, lesion, or
bruising. The patient also denied headache, loss of consciousness, impaired vision, hearing loss,
ear pain, altered sense of smell, postnasal drainage, sore throat, or hoarseness. He denied cough,
shortness of breath, chest pain, palpitations, claudication, history of anemia, nausea, vomiting, or
constipation. He has no known endocrine disorders, no genitourinary symptoms, no joint pain or
stiffness, and denies any syncopal episodes, tremors, or seizures. The patient discussed that due
to his employment and busy time of the year he was experiencing somewhat more stress than
usual and admitted he was not getting adequate nightly rest.
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Physical Exam
The patient’s vital signs were taken prior to physical examination and he was found to
have a pulse of 88 beats per minute, blood pressure of 152/92 mmHg, respiratory rate of 16
breaths per minute, temperature of 97.4 degrees Fahrenheit, and weight of 140 pounds. The
patient is fifty-two years old, and a general appearance of a middle aged Caucasian male with an
appropriate weight for height and no obvious nutritional deficits. There were no evident
cognitive, speech or language defects. The patient did have a visibly erythematous patch
measuring 5x3cm, with multiple confluent, herpetiform vesicles to the lateral aspect of his left
orbit at the level of the maxillary (V2) dermatome. The patient had otherwise normal facial
symmetry and characteristics, 20/20 visual acuity with Snellen eye chart, no peripheral field
deficits, intact extraocular movements, and equal pupillary response to light and accommodation.
The patient’s conjunctiva were clear and sclera were white. No abnormal findings were found on
assessment of the patient’s ears, nose, or throat. The patient had no thyroid tenderness or
nodules, normal anterior/posterior chest diameter, and his breath sounds were clear bilaterally to
auscultation. The patient had a regular heart rate and rhythm with normal S1 and S2 heart tones.
The patient’s abdomen was non-tender with no masses found to palpation. There were also no
other skin lesions or rashes found throughout the course of the physical examination.
Management of Care
The patient was found to have several pertinent findings classical for making the
diagnosis of herpes zoster (shingles). The patient had a unilateral erythematous vesicular rash
that did not cross the midline and remained with the maxillary (V2) dermatome. The patient did
not have any complaints of pain, however described it to be quite pruritic.
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The differential diagnosis of herpes zoster is usually made clinically and without
laboratory testing. The classic vesicular lesions along a single dermatome confirm diagnosis
(Whitley, 2015). During the prodromal period, however, the diagnosis can be quite difficult and
is usually confirmed once the lesions have appeared.
The treatment regimen for herpes zoster include a regimen of antivirals and symptomatic
treatment including adequate analgesia. Patients should be started on acyclovir, valacyclovir, or
famciclovir for seven days as soon as diagnosis is made and within forty eight to seventy two
hours of rash onset (Whitley, 2015). Patients with ocular manifestations should be treated with a
ten day course of the oral antivirals. Valacyclovir and famcyclovir are the preferred treatments in
terms of efficacy due to pharmacokinetics and dynamics, however may be cost prohibitive. It is
also important that patients are provided with adequate analgesia for acute neuritis and
postherpetic neuralgia which may include regimens of narcotics, nonnarcotics, or both (Whitley,
2015). Additionally, some studies have shown that treatment with glucocorticoids accelerated
return of quality of life and decreased the length of use of analgesics (Whitley, 2015).
The patient for this case study was educated on the overall cause, course, and
manifestations of herpes zoster. He was also informed of the potential risk of zoster opthalmicus
and that I would suggest referring him to an ophthalmologist for prevention of ocular
impairment. Due to cost, the patient was started on acyclovir 800mg orally five times per day for
ten days. For analgesia, the patient was given gabapentin 300mg orally three times per day along
with tramadol 50mg every six hours. I discussed with the patient that his response to gabapentin
and tramadol may cause drowsiness so he should not take these medications while at work. We
also discussed the importance of keeping the vesicles covered and avoid exposure to
unvaccinated and nonimmune individuals to prevent transmission of the virus.
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Other considerations for this patient include his general health maintenance. The patient
does not currently have a primary care provider and is not up to date with his recommended
health screenings. The patient has recently enrolled in a health insurance plan and the next step
for this patient would be to establish care with a primary care provider. The patient is due for
immunizations, as well as colon cancer, blood pressure, cholesterol, and diabetes screening
(MedlinePlus, 2015). The patient was actually hypertensive at his visit and this was discussed
with him. I stressed that it was very important that he establish care with a provider to ensure that
all of these needs were addressed.
Literature Review
Search Strategies
For the process of reviewing literature in support of this topic, I electronically accessed
the Harley E. French Library of the Health Sciences at the University of North Dakota,
specifically utilizing two search engines, the Cumulative Index to Nursing and Allied Health
Literature (CINAHL) and PubMed. My topic focused on prevention of postherpetic neuralgia by
increasing specific cell mediated immunity via administration of a Varicella Zoster Vaccine.
Again, the trade name for this vaccine is “ZostaVax”. Based on this information I was able to
focus my search criteria to “postherpetic neuralgia”, “prevention”, “herpes zoster”, “zoster
vaccine”, and “ZostaVax”.
With “English” and “results within the last ten years” filters applied, my search yielded a
total of nine applicable articles that were accessible for online viewing. Two of which were
retrieved from the CINAHL search and nine from the PubMed database.
Findings
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There have been a number of trials focused on the use of a varicella zoster vaccine to
reduce the incidence of herpes zoster. These include the Shingles Prevention Study (SPS),
Zostavax ® Efficacy and Safety Trial (ZEST), Short Term Persistence Study (STPS), and Long
Term Persistence Study (LTPS). These studies along with findings from several other cohort and
longitudinal studies will be discussed to reinforce the outcome of reduced intensity and length of
postherpetic neuralgia symptoms related to varicella zoster immunization.
Shingles Prevention Study. The shingles prevention study (SPS) is a clinical study with
a subject population of 38,546. The research was based around the fact that herpes zoster and
postherpetic neuralgia are known to have many deleterious effects and substantial increases in
morbidity of older adults (Oxman & Levin, 2008). In addition, the researchers understood that
the incidence of both conditions increased as the age related cell mediated immunity to varicella
zoster declined. Since varicella zoster vaccines increase this immunity, their hypothesis was that
vaccination would provide protection to the study population from both herpes zoster and
postherpetic neuralgia (Oxman & Levin, 2008).
The SPS was a multicenter, double-blinded, placebo controlled, randomized clinical trial
made up of immunocompetent participants over the age of sixty years old (Gabutti et al., 2014).
Study participants were followed for 182 days. The participants must have had a memory of
varicella zoster or resided for at least thirty years in an endemic region of the virus. Patients who
were excluded from the trial included those with no history of zoster, allergy to any components
of the vaccine, or immunosuppression of any kind (Gabutti et al., 2014). The primary focus of
this study was to determine safety and efficacy of the varicella vaccine with specific evaluation
of decreased burden of illness. Burden of illness was based on “incidence, severity and duration
of acute and chronic pain related to herpes zoster during a follow-up period of at least six
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months” (Gabutti et al., 2014, p. 132). The secondary focus of this trial was to evaluate the
effectiveness of the vaccine to reduce incidence of postherpetic neuralgia.
The results of the Shingles Prevention Study were quite significant. The overall level of
efficacy was 51.3% with a reduction of burden of illness of 61.1% (Gabutti et al., 2014). The
overall effectiveness of the vaccine to prevent postherpetic neuralgia was 66.5% (Gabutti et al.,
2014). In ages 60-69 there was 65.7% efficacy with a 66.8% reduction in ages greater than 70
years. Overall, there was a 73% reduction in the number of cases of herpes zoster with “severe
and long-lasting pain” (Kanbayashi & Hosokawa, 2013, p.2)
Short Term Persistence Substudy. The Short Term Persistence Substudy (STPS) began
as a method to assess and track the efficacy of the zoster vaccine. This study reenrolled
participants from the Shingles Prevention Study. The population was made up of 7,320 vaccine
and 6,950 placebo recipients (Schmader et al., 2012). The researchers kept the methods of
surveillance, case determination, and follow-up exactly the same as the SPS trial. The “vaccine
efficacy for herpes zoster burden of illness, incidence of postherpetic neuralgia, and incidence of
herpes zoster were assessed for the STPS population, for the combined SPS and STPS
population, and for each year through year 7 after vaccination” Schmader et al., 2012, p. 1320).
Results of the substudy were not as robust as the original Shingles Prevention Study. The
vaccine’s efficacy on burden of illness dropped to 50.1% from 61.1% (Schmader et al., 2012).
Postherpetic neuralgia efficacy decreased from an incidence of 66.5% to 60.1%. The overall
efficacy of the vaccine decreased from 51.3% to 39.6%, however the researchers note that this
difference was not statistically significant. Final conclusions of the STPS revealed that there was
a decrease in the vaccine efficacy after the first year of administration with subsequent declines
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in the years after. The efficacy of the vaccine did, however, remain statistically significant for 5
years post vaccination (Schmader et al., 2012).
Long Term Persistence Substudy. The Long Term Persistence Substudy (LTPS) was
conducted similar to the STPS, however it monitored vaccine efficacy from 5 up to 11 years
postvaccination (Morrison et al., 2015). The LTPS population was derived from participants of
the Shingles Prevention Study. Unlike the Short Term Persistence Study, however, did not utilize
placebo recipients and therefore unable to have an unvaccinated control group. The Long Term
Persistence Substudy enrolled a total 6,867 SPS vaccine recipients.
The results of the study found that the estimated vaccine efficacy for herpes zoster burden
of illness dropped to 37.3% from 61.1% (Morrison et al., 2012). Efficacy of postherpetic
neuralgia declined to 35.4% from 66.5% and overall efficacy for prevention of herpes zoster
declined from 51.3% to 21.1% (Morrison et al., 2012). All three of these measures decreased
from years 7-11. Efficacy for reduction of burden of illness remained greater than zero through
year ten after vaccination, however the vaccines efficacy of decreasing incidence of herpes zoster
remained significantly greater than zero through year 8 of study (Morrison et al., 2012). Overall
conclusions revealed that vaccine efficacy waned over time.
Zoster Efficacy and Safety Trial. The Zoster efficacy and Safety Trial (ZEST) was
conducted in North America and Europe from October 2007-January 2010. This study was a
double-blinded, placebo controlled, randomized clinical trial. Similar to the SPS, ZEST
participants required a positive memory of varicella or lived at least 30 years in a region endemic
to the virus (Gabutti et al., 2014). Subjects of this trial were 50-59 years of age and given a single
dose zoster vaccine or placebo. A total of 22,439 pariticpants were enrolled in this study (Gabutti
et al., 2014).
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The primary study endpoint of this trial was evaluating the overall incidence of herpes
zoster post varicella vaccination (Keating, 2013). Total efficacy was found to be 69.8% (Gabutti
et al., 2014). Total efficacy was staged into four time periods; 0-0.5 years, 0.5-1 years, 1.0-1.5
years, and greater than 1.5 years. Overall, efficacy for these time periods were 76.9%, 64.0%,
65.2%, and 75.3% (Keating, 2013). Severity-by-duration pain scores were also lower in the
vaccinated population versus the placebo group. The reduction in pain score for the vaccinated
group was 73.0% (Keating, 2013). It is important to note however that there was a major
difference between the collection time period of ZEST and SPS pain/burden of illness scores of
21 days (ZEST) and 182 days (SPS) (Keating, 2013).
Additional Research. Several other studies have been conducted focusing on the
efficacy of the varicella vaccine in the reduction of postherpetic neuralgia. Tseng et al. (2015, p.
1222) conducted a cohort study of “1,155 individuals who were vaccinated against herpes zoster
at age ≥60 years and had an herpes zoster episode after vaccination”. This cohort was matched at
a 1:1 ratio with unvaccinated patients of same sex and age. Medical records were reviewed by
trained medical residents to monitor pain at intervals up to six months after diagnosis of herpes
zoster and compared with the pain levels of unvaccinated patients (Tseng et al., 2015). Their
findings concluded that vaccination for herpes zoster is “associated with a lower risk of PHN in
women but not in men” (Tseng et al., 2015).
Bricout et al. (2014, p.1) conducted a “longitudinal, prospective study in 108 general
practices throughout Italy to assess how many immunocompetent patients aged ≥50 years with
newly diagnosed herpes zoster develop herpes zoster associated pain, its duration and
management over 6 months”. The researchers assessed pain via direct questioning and classified
postherpetic neuralgia by symptoms of pain lasting greater than 3 months. The group also
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assessed quality of life via questionnaire. At the time of this study, 2009-2010, implementation
of a varicella vaccine was not implemented and no mention of immunization history was
discussed. The researchers also discussed that many, yet not all, patients received recommended
antiviral therapy.
Bricout et al. (2014) discovered that 89.6% of the group described pain related to herpes
zoster. Of them, 20.6% had pain at 3 months and 9.2% of patients had pain at 6 months. They
concluded that herpes zoster and postherpetic neuralgia do carry a burden on patients, especially
elderly, and there is a need for prevention and intervention to reduce the burden of illness in this
population.
Discussion
Postherpetic neuralgia carries a serious burden of illness and decreases quality of life
especially in the elderly population. The pain related to PHN may be responsible for “depression,
fatigue, insomnia, altered activities of daily living, and decreased socialization” (Tseng et al.
2015, p. 1222). These patients may also have symptoms of anorexia, decreased physical activity,
and experience altered mental status. These effects can be especially detrimental in the elderly
population. Treatment options are often initiated at time of onset of rash and require accurate
clinical diagnosis. Effectiveness of treatment options vary on an individual basis and elderly
patients may not be candidates for many pharmacological regimens due to complex
comorbidities. Prevention or symptom reduction is vital to ensuring quality of life and decreasing
the burden of illness in this population.
There has been a significant amount of research conducted regarding the ability of the
Zostavax vaccine to prevent or decrease morbidity related to post herpetic neuralgia. The
foundation of the research focused on four clinical trials: SPS, LTPS, ZEST, and STPS. All of
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the studies found that patients who receive the vaccination have significantly less risk of
developing herpes zoster. In addition, the vaccine decreases burden of illness for a period of at
least 5 years with benefits through 10 years post-vaccination. Therefore, this independent study
found that the Zostavax decreases the incidence of postherpetic neuralgia by decreasing the
incidence of herpes zoster as well as the duration and intensity of related symptoms.

Learning Points


Zoster vaccine is proven to be statistically effective for prevention of herpes zoster and
postherpetic neuralgia for 5 years.



Zoster vaccine decreases intensity and duration of postherpetic neuralgia.



New guidelines are needed to address the vaccine’s decreased efficacy after 5 years.



Postherpetic neuralgia may be more severe in males, however more research is needed to
confirm this assumption.
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